Millendo Therapeutics reports Q2 EPS (74c), consensus (81c)
"Our ZEPHYR pivotal Phase 2b/3 clinical study in PWS patients is off to a strong start, and we remain on track to report topline results from the Phase 2b portion of the study in the first half of 2020," said Julia Owens, President and CEO of Millendo Therapeutics. "In addition, our Phase 2b clinical study of nevanimibe in CAH is enrolling patients under an amended protocol. We expect to provide an update on timelines for the CAH study in the second half of 2019. We are announcing today our decision to discontinue the Phase 2 study of nevanimibe in Cushing's syndrome, based on an analysis of the feasibility of patient recruitment and a reprioritization of resources. While this decision was a difficult one, we believe that we are now able to better optimize investments across our portfolio of potential novel therapies in areas of significant unmet need. In line with this commitment, we are excited today to announce the selection of a new compound to begin preclinical development required to support a first-in-human study, MLE-301 for the treatment of vasomotor symptoms associated with menopause. This selective NK3R antagonist enables us to leverage our expertise in VMS drug development."